Immunomodulatory Effects of Plant Polysaccharides in Chronic Inflammatory Diseases: From Innate to Adaptive Immunity

Main Article Content

Ponazhagan, Baskaran Kuppusamy, Ibrokhim Sapaev, Komal Patel, Santosh Kumar Singh, Rajeev Sharma, Jeniffer Raj

Abstract

Chronic inflammatory and autoimmune diseases—including inflammatory bowel disease, rheumatoid arthritis, asthma and metabolic inflammation—arise from a failure of immune homeostasis in which innate over-activation and dysregulated adaptive responses reinforce one another. Plant polysaccharides, structurally complex biomacromolecules from herbs, fruits and fungi, have emerged as broad-spectrum immunomodulators that act, uniquely, along the entire innate-to-adaptive continuum. Recognised as pathogen-associated-molecular-pattern (PAMP)-like ligands by pattern-recognition receptors (PRRs)—chiefly Toll-like receptor 4 (TLR4), Dectin-1, the mannose receptor and complement receptor 3—they engage MyD88–NF-κB, Syk–Card9 and MAPK signalling to shape macrophage polarisation, dendritic-cell maturation and natural-killer-cell activity. Through dendritic-cell bridging they then direct the adaptive response, rebalancing the Th1/Th2, Th17/Treg and effector/regulatory axes whose distortion drives chronic inflammation. A third, indirect route operates through the gut microbiota: non-digestible polysaccharides are fermented to short-chain fatty acids that promote regulatory T-cell differentiation and epithelial-barrier integrity.
This review synthesises these mechanisms, emphasising the structure–activity relationships—molecular weight, backbone linkage, branching and conformation—that govern potency, and the context-dependent, bidirectional nature of polysaccharide immunomodulation. Compiled preclinical data show 45–88% shifts in pro- versus anti-inflammatory mediators, restoration of Th17/Treg balance, and 45–62% reductions in disease-severity markers across models of chronic inflammation. The review concludes that plant polysaccharides are versatile homeostatic immunomodulators whose translation now depends on structural standardisation, resolution of oral-bioavailability limitations, and rigorous clinical validation.

Article Details

Section
Articles